Cognet-X Release: Vytorin Coverage with Leading Health Plans Revisited – See Uptake of Generic Simvastatin and Crestor Without Need for Widespread Formulary Changes

PHILADELPHIA--(BUSINESS WIRE)--According to follow-up research from Cognet-X, Inc., conducted in the first week of April, pharmacy and medical executives at leading health plans still do not foresee widespread changes in how their organizations will cover Merck/Schering-Plough’s cholesterol reducer Vytorin.